Latest Insider Transactions at 60 Degrees Pharmaceuticals, Inc. (SXTP)
This section provides a real-time view of insider transactions for 60 Degrees Pharmaceuticals, Inc. (SXTP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of 60 DEGREES PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of 60 DEGREES PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2024
|
Cheryl Xu Director |
BUY
Open market or private purchase
|
Direct |
5,000
+10.85%
|
$5,000
$1.7 P/Share
|
|
May 16
2024
|
Paul Field Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.22%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Tyrone Miller CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+7.82%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Stephen Toovey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+22.22%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Cheryl Xu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+0.87%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Charles W Allen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.22%
|
$0
$0.22 P/Share
|
|
May 16
2024
|
Geoffrey S Dow President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+2.18%
|
$0
$0.22 P/Share
|
|
Apr 12
2024
|
Tyrone Miller CFO |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+27.04%
|
$0
$0.27 P/Share
|
|
Apr 12
2024
|
Geoffrey S Dow President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
68,000
+8.36%
|
$0
$0.27 P/Share
|
|
Feb 01
2024
|
Cheryl Xu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+25.0%
|
-
|
|
Jan 31
2024
|
Cheryl Xu Director |
BUY
Open market or private purchase
|
Direct |
200,000
+32.0%
|
$0
$0.38 P/Share
|
|
Jan 31
2024
|
Geoffrey S Dow President and CEO |
BUY
Open market or private purchase
|
Direct |
25,974
+3.56%
|
$0
$0.38 P/Share
|
|
Jul 28
2023
|
Knight Therapeutics Inc |
SELL
Conversion of derivative security
|
Indirect |
2,162
-2.67%
|
-
|
|
Jul 28
2023
|
Knight Therapeutics Inc |
BUY
Conversion of derivative security
|
Indirect |
45,560
+3.8%
|
$182,240
$4.75 P/Share
|